Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications IgAN

Long-Term Outcomes in IgA Nephropathy

View
Posters IgAN

Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy (IgAN): Subgroup Analyses of 2-Year Results from the Pivotal Phase 3 PROTECT Trial – Encore presentation

Learn More
Posters IgAN

Effects of Proteinuria Reduction on Delay of Kidney Failure in Patients With Immunoglobulin A Nephropathy

Learn More
Downloadable Resources IgAN

PROTECT: Two-Year Efficacy and Safety Findings of Sparsentan

Learn more
Publications IgAN

Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephopathy (PROTECT): 2-year Results From a Randomised Active-Controlled Phase 3 Trial

View
Publications IgAN

Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease

View
Publications IgAN

Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgA immune complexes in a mouse model of IgA nephropathy

View
Publications IgAN

Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

View
Medical Information IgAN

FILSPARI (sparsentan): Impact on Male Fertility

Learn more
Medical Information IgAN

FILSPARI  (sparsentan): Use in Patients With Severely Decreased eGFR in IgA Nephropathy

Learn more
Publications IgAN

Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Publications IgAN

Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database

View
Publications IgAN

Sparsentan is superior to losartan in the gddY mouse model 1 of IgA nephropathy

View